Devyser and Thermo Fisher Scientific expand the collaboration for post-transplant NGS products by adding Brazil
Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including...
Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including...
Devyser’s novel test for detecting donor-derived cell-free DNA in blood samples from...
Devyser has inaugurated its CLIA-certified laboratory in Atlanta, Georgia. The laboratory will...
Devyser is thrilled to announce the launch of two new products, Devyser LynchFAP and Devyser BRCA...
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
“The first quarter of the year saw continued strong growth, record gross margin and the launching...
Devyser is today announcing that the company’s clinical testing laboratory in Roswell in Atlanta,...
Devyser has been awarded the Swecare Export Award 2023. The prize is awarded to companies that...
Collaboration and distribution agreement with Thermo Fisher Scientific Thermo Fisher Scientific...
Devyser´s annual report 2022 has today been published on the company´s website. The report is...
With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier,...